conduritol epoxide has been researched along with Parkinson Disease in 6 studies
conduritol epoxide: conduritol C epoxide refers to the (epi & neo)-isomers; structure
conduritol epoxide : An epoxide resulting from the epoxidation of the double bond of a conduritol.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ruz, C | 1 |
| Alcantud, JL | 1 |
| Vives, F | 1 |
| Arrebola, F | 1 |
| Hardy, J | 1 |
| Lewis, PA | 1 |
| Manzoni, C | 1 |
| Duran, R | 1 |
| Papadopoulos, VE | 1 |
| Nikolopoulou, G | 1 |
| Antoniadou, I | 1 |
| Karachaliou, A | 1 |
| Arianoglou, G | 1 |
| Emmanouilidou, E | 1 |
| Sardi, SP | 1 |
| Stefanis, L | 2 |
| Vekrellis, K | 1 |
| Kuo, CL | 1 |
| Kallemeijn, WW | 1 |
| Lelieveld, LT | 1 |
| Mirzaian, M | 1 |
| Zoutendijk, I | 1 |
| Vardi, A | 1 |
| Futerman, AH | 1 |
| Meijer, AH | 1 |
| Spaink, HP | 1 |
| Overkleeft, HS | 1 |
| Aerts, JMFG | 1 |
| Artola, M | 1 |
| Dermentzaki, G | 1 |
| Dimitriou, E | 1 |
| Xilouri, M | 1 |
| Michelakakis, H | 1 |
| Ginns, EI | 1 |
| Mak, SK | 1 |
| Ko, N | 1 |
| Karlgren, J | 1 |
| Akbarian, S | 1 |
| Chou, VP | 1 |
| Guo, Y | 1 |
| Lim, A | 1 |
| Samuelsson, S | 1 |
| LaMarca, ML | 1 |
| Vazquez-DeRose, J | 1 |
| Manning-Boğ, AB | 1 |
| Yap, TL | 1 |
| Gruschus, JM | 1 |
| Velayati, A | 1 |
| Westbroek, W | 1 |
| Goldin, E | 1 |
| Moaven, N | 1 |
| Sidransky, E | 1 |
| Lee, JC | 1 |
6 other studies available for conduritol epoxide and Parkinson Disease
| Article | Year |
|---|---|
Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line.
Topics: Cell Line; Cell Line, Tumor; Enzyme Inhibitors; Glioma; Glucosylceramidase; Humans; Inositol; Leucin | 2022 |
Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Brain; Disease Models, Animal; Exosomes; Glucosylceramidase; Humans; Inosi | 2018 |
In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling.
Topics: Animals; beta-Glucosidase; Brain; Cyclohexanols; Disease Models, Animal; Enzyme Assays; Glucosylcera | 2019 |
Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells.
Topics: alpha-Synuclein; Animals; Autophagy; Cell Differentiation; Cell Line; Gaucher Disease; Glucosylceram | 2013 |
Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction.
Topics: alpha-Synuclein; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Evoked Potentials, Moto | 2014 |
Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
Topics: alpha-Synuclein; Amino Acid Substitution; Cell Line, Tumor; Enzyme Inhibitors; Gaucher Disease; Gluc | 2011 |